Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a group of four atypical (second-generation) antipsychotic drugs: quetiapine, olanzapine, risperidone, and aripiprazole. These medications are primarily used for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions. They act mainly by modulating neurotransmitter activity in the brain—primarily dopamine D2 receptor antagonism (except for aripiprazole, which is a partial agonist at D2), as well as effects on serotonin receptors (notably 5-HT2A antagonism). Each drug has a unique receptor binding profile that influences its efficacy and side effect spectrum. Quetiapine is known for its sedative properties; olanzapine is associated with significant metabolic side effects; risperidone can cause hyperprolactinemia; and aripiprazole tends to have fewer metabolic adverse effects due to its partial agonist action at dopamine receptors[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quetiapine or olanzapine or risperidone or aripiprazole.